Ibrutinib
Ibrutinib · IBRUTINIB 140 mg/1 · Capsule · Catalent Pharma Solutions, LLC
NDC 11014-0163-03 · 1 BAG in 1 DRUM / 113636 CAPSULE in 1 BAG · DRUG FOR FURTHER PROCESSING · View full market →
Bulk ingredient — not a finished product
This NDC is a raw material (drug for further processing) sold to drug manufacturers or compounders, not a product pharmacies dispense. Retail pricing, TE codes, fragility scores, and shortage reports don't apply to bulk listings — those attach to finished products made from this ingredient.
Medicare Part D
All Part D pricing →Matched to CMS's representative package for this drug (NDC 57962-0140-09) — same generic, strength, and dosage form. CMS prices one NDC per drug concept, not every package.
ⓘ How this was built
- CMS quarterly Prescription Drug Plan Formulary & Pricing files (SPUF)
Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 10 quarters since 2024.
NADAC price per unit
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Supply fragility
Not scored — fragility is computed for NADAC-priced NDCs.
Is this a "specialty" drug?
There's no legal definition — it meets 1 of 6 public criteria. Why that matters →
- Part D specialty tier
- Costs ≥ $950/fill · avg $15,478.17 per prescription
- Biologic (BLA)
- Injectable / infused
- Orphan-drug exclusivity
- REMS program
Regulatory
- Application
- —
- TE code
- —
- Approval date
- —
- Patents / exclusivity
- —
Shortage history
No FDA shortage reports for this drug or its presentations.
Recalls (this NDC)
No enforcement reports list this package NDC.
Manufacturers of Ibrutinib (Capsule)
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| AbbVie Inc. | IBRUTINIB 140 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| AbbVie Inc. | IBRUTINIB 70 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Catalent Pharma Solutions, LLC | IBRUTINIB 140 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Catalent Pharma Solutions, LLC | IBRUTINIB 70 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Pharmacyclics LLC | IBRUTINIB 140 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Pharmacyclics LLC | IBRUTINIB 70 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
Cite this page
DrugDashboards, "Ibrutinib — NDC 11014-0163-03," retrieved September 3, 2026, https://drugdashboards.com/drug/11014016303.
Free to cite with attribution — see how the data is put together.